United Therapeutics (UTHR) announced full enrollment of the TETON 1 study evaluating the use of Tyvaso or treprostinil, inhalation solution or ...

United Therapeutics has scored a regulatory green light to start clinical trials for its genetically modified pig kidneys to ...

United Therapeutics could eventually use the genetically edited swine to grow organs for human transplant recipients. A public biotechnology company is planning a large project in northeast ...

United Therapeutics Corporation (Nasdaq ... the timing and enrollment of our planned UKidney clinical trial; our plans to seek FDA approval of the UKidney following completion of the clinical ...

The company plans to submit a Biologics ... affect investor confidence. Outlook Therapeutics is still in the investigational stage for its product in the United States, suggesting uncertainty ...

RESEARCH TRIANGLE PARK, N.C. - United Therapeutics (NASDAQ:UTHR ... The company is preparing an investigational new drug application for the UKidney, with plans to initiate a clinical study in 2025, ...

Michael Benkowitz, President and COO of United Therapeutics Corp (NASDAQ:UTHR), recently executed a series of stock transactions, according to a recent SEC filing. On February 3, Benkowitz sold shares ...

RESEARCH TRIANGLE PARK, N.C. - United Therapeutics (NASDAQ ... an investigational new drug application for the UKidney, with plans to initiate a clinical study in 2025, pending FDA clearance.

In this article, we are going to take a look at where Kazia Therapeutics Limited (NASDAQ ... particularly the United States. Morgan Stanley has raised its year-end 2025 price target for the ...